SN50 peptide

contains a translocation signal from the NF-kappaB p50 subunit; amino acid sequence in first source

Also Known As:

NF-kappaB SN50; NF-kappaB p50 inhibitor; SC 3060; SC-3060; SC3060; SN-50 peptide

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Anaplastic Thyroid Carcinoma 11/01/2002 - "The results showed that TNF-alpha can induce activation of NF-kappaB and that the activation and translocation of NF-kappaB into the nucleus is responsible for promoting the 3-D cytomorphologic differentiation of anaplastic thyroid carcinoma cells, which was inhibited by the NF-kappaB translocation inhibitor, NF-kappaB SN50. " 11/01/2002 - "The effect of NF-kappaB SN50, a NF-kappaB translocation inhibitor, on cytomorphologic changes induced in anaplastic thyroid carcinoma cells by TNF-alpha also was studied. "
2.	Necrosis 03/01/2005 - "Co-treatment of the cells with inhibitors of PI-3 kinase (LY294002) and nuclear factor kappa B (NF-kappaB) (SN50) pathways leads to an earlier significantly increased cytotoxicity, respectively in the form of apoptosis and necrosis. "

1.	NF-kappa B (NF-kB)
2.	Phosphatidylinositol 3-Kinases (PI 3 Kinase)
3.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
4.	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one